SCHEMBL5835494

SCHEMBL5835494

Cc1cc(Br)ccc1S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 12/20 0.70
GHSR Q92847 1/20 0.49
BRD4 O60885 1/20 0.44
BRD1 O95696 1/20 0.44
BRPF1 P55201 1/20 0.44
BRPF3 Q9ULD4 1/20 0.44
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
SGK1 O00141 1/20 0.40
ERBB2 P04626 1/20 0.40
EPHA2 P29317 1/20 0.40
KDR P35968 1/20 0.40
EPHB4 P54760 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835495 1.00 UTS2R (0.70) UTS2RGHSRBRD4BRD1BRPF1
SCHEMBL8340302 0.90 UTS2R (0.69) UTS2RMEN1ALDH1A1LMNAMAPT
SCHEMBL5835327 0.88 UTS2R (0.67) UTS2RLMNAERBB2EPHA2KDR
SCHEMBL5835323 0.88 UTS2R (0.67) UTS2RLMNAERBB2EPHA2KDR
SCHEMBL5835310 0.88 UTS2R (0.78) UTS2RMEN1ALDH1A1LMNAMAPT
SCHEMBL5835316 0.88 UTS2R (0.78) UTS2RMEN1ALDH1A1LMNAMAPT
SCHEMBL8339797 0.87 UTS2R (0.71) UTS2RGHSRBRD4BRD1BRPF1
SCHEMBL5835158 0.86 UTS2R (0.65) UTS2R
SCHEMBL5835157 0.86 UTS2R (0.65) UTS2R
SCHEMBL8340488 0.86 UTS2R (0.69) UTS2RMEN1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US claimed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP claimed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US claimed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP claimed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP disclosed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US disclosed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152906-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885GHSR 715/4885BRD4 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.